Eric Deutsch

USPTO Granted Patents = 8 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 21)

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 33(Granted Patents)

Company Filing History:

7 out of 96

Institut Gustave Roussy

Université Paris-saclay

5. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12511747 - Method for training a decision system for segmenting medical images (2025-12-30),

2. 11603568 - NOX2 as a biomarker of radiotherapy efficiency in cancer patients (2023-03-14),

3. 11517575 - Use of minaprine to reduce tumor growth (2022-12-06),

4. 11471463 - Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy (2022-10-18),

5. 11021442 - Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino] ethanethiol formulation (2021-06-01),

6. 10969380 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2021-04-06),

7. 9726661 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2017-08-08),

8. 6723712 - Antiviral agent for use in treatment of cancer (2004-04-20),

Title: Innovations and Contributions of Eric Deutsch

Introduction

Eric Deutsch is a prominent inventor based in Paris, France, known for his significant contributions to cancer research and treatment. With a total of seven patents to his name, Deutsch has made strides in understanding the molecular mechanisms involved in cancer therapies.

Latest Patents

One of his latest patents focuses on "NOX2 as a biomarker of radiotherapy efficiency in cancer patients." This invention highlights the role of tumor-associated macrophages in the response to radiotherapy. Deutsch and his team discovered that ionizing radiation activates macrophages through the expression of interferon-regulatory factor 5 (IRF5), leading to a pro-inflammatory phenotype. They identified that the activation of the Ataxia telangiectasia mutated (ATM) kinase is crucial for this process. Furthermore, they demonstrated that NADPH oxidase 2 (NOX2)-dependent reactive oxygen species (ROS) production is essential for ATM activation. Their findings suggest that targeting this signaling pathway could enhance the effectiveness of radiotherapy in treating locally advanced rectal cancer.

Another notable patent involves the "Use of minaprine to reduce tumor growth." This invention pertains to the administration of Minaprine dihydrochloride and its analogs to patients suffering from cancer, aiming to reduce tumor growth effectively.

Career Highlights

Throughout his career, Eric Deutsch has worked with esteemed institutions, including the Institut Gustave Roussy, where he has contributed to groundbreaking research in oncology. His work has been pivotal in advancing the understanding of cancer treatment and improving patient outcomes.

Collaborations

Deutsch has collaborated with notable colleagues, including Jean-Luc Perfettini, enhancing the depth and impact of his research endeavors.

Conclusion

Eric Deutsch's innovative work in cancer research, particularly through his patents, showcases his commitment to improving therapeutic strategies for patients. His contributions are vital in the ongoing fight against cancer, and his research continues to inspire advancements in the field.

This text is generated by artificial intelligence and may not be accurate.